120 related articles for article (PubMed ID: 637906)
41. Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues.
Chabner BA; Young RC
J Clin Invest; 1973 Aug; 52(8):1804-11. PubMed ID: 4719662
[TBL] [Abstract][Full Text] [Related]
42. [Studies on high-dose methotrexate with citrovorum factor rescue therapy in children: analysis of bone marrow cell kinetics by flow cytometry].
Tsurusawa M; Sasaki K; Matsuoka H; Katano N; Fujimoto T
Gan To Kagaku Ryoho; 1985 Sep; 12(9):1827-32. PubMed ID: 3876075
[TBL] [Abstract][Full Text] [Related]
43. Potentiation of the antitumor activity of methotrexate by concurrent infusion of thymidine.
Semon JH; Grindey GB
Cancer Res; 1978 Sep; 38(9):2905-11. PubMed ID: 679199
[No Abstract] [Full Text] [Related]
44. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
45. Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).
Melink TJ; Von Hoff DD; Kuhn JG; Hersh MR; Sternson LA; Patton TF; Siegler R; Boldt DH; Clark GM
Cancer Res; 1985 Jun; 45(6):2859-65. PubMed ID: 3986813
[TBL] [Abstract][Full Text] [Related]
46. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
47. [l-folinic acid versus racemic folinic acid in the treatment of leukemia in children with high dose of methotrexate].
Etienne MC; Thyss A; Bertrand Y; Rubie H; Milano G
Bull Cancer; 1993 Apr; 80(4):357-63. PubMed ID: 8173189
[TBL] [Abstract][Full Text] [Related]
48. Methotrexate and dipyridamole combination chemotherapy based upon inhibition of nucleoside salvage in humans.
Willson JK; Fischer PH; Remick SC; Tutsch KD; Grem JL; Nieting L; Alberti D; Bruggink J; Trump DL
Cancer Res; 1989 Apr; 49(7):1866-70. PubMed ID: 2924325
[TBL] [Abstract][Full Text] [Related]
49. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
Joannon P; Oviedo I; Campbell M; Tordecilla J
Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
[TBL] [Abstract][Full Text] [Related]
50. NTP technical report on the toxicity studies of Riddelliine (CAS No. 23246-96-0) Administered by Gavage to F344 Rats and B6C3F1 Mice.
Chan P
Toxic Rep Ser; 1993 Dec; 27():1-D9. PubMed ID: 12209179
[TBL] [Abstract][Full Text] [Related]
51. Kinetic alterations induced by 5-fluorouracil in bone marrow, intestinal mucosa, and tumor.
Myers CE; Young RC; Chabner BA
Cancer Res; 1976 May; 36(5):1653-8. PubMed ID: 1268826
[TBL] [Abstract][Full Text] [Related]
52. Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil.
Klubes P; Cerna I
Cancer Res; 1983 Jul; 43(7):3182-6. PubMed ID: 6850628
[TBL] [Abstract][Full Text] [Related]
53. Sequential infusions of methotrexate and 5-fluorouracil in advanced cancer: pharmacology, toxicity, and response.
Benz C; DeGregorio M; Saks S; Sambol N; Holleran W; Ignoffo R; Lewis B; Cadman E
Cancer Res; 1985 Jul; 45(7):3354-8. PubMed ID: 4005858
[TBL] [Abstract][Full Text] [Related]
54. New approaches to cancer chemotherapy with methotrexate.
Frei E; Jaffe N; Tattersall MH; Pitman S; Parker L
N Engl J Med; 1975 Apr; 292(16):846-51. PubMed ID: 1078714
[No Abstract] [Full Text] [Related]
55. Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure.
van den Bongard HJ; Mathĵt RA; Boogerd W; Schornagel JH; Soesan M; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2001 Jun; 47(6):537-40. PubMed ID: 11459208
[TBL] [Abstract][Full Text] [Related]
56. Achievement of long duration methotrexate exposure with concurrent low dose thymidine protection: influence of methotrexate pharmacokinetics.
Howell SB; Tamerius RK
Eur J Cancer (1965); 1980 Nov; 16(11):1427-32. PubMed ID: 7227419
[No Abstract] [Full Text] [Related]
57. Rescue from high-dose methotrexate with 5-methyltetrahydrofolate.
Reggev A; Djerassi I
Cancer Treat Rep; 1986 Feb; 70(2):251-3. PubMed ID: 3948189
[TBL] [Abstract][Full Text] [Related]
58. [Radiational basis and practice of the citrovorum factor (Leucovorin) protection after high-dose methotrexate therapy. High-dose methotrexate/leucovorin].
Sauer H; Schalhorn A
Onkologie; 1980 Apr; 3(2):64-71. PubMed ID: 6994007
[TBL] [Abstract][Full Text] [Related]
59. Letter: Methotrexate with citrovorum-factor rescue.
Falk L
N Engl J Med; 1975 Jun; 292(26):1406-7. PubMed ID: 1079571
[No Abstract] [Full Text] [Related]
60. Modulation versus rescue of antimetabolite toxicity by salvage metabolites administered by continuous infusion.
Grindey GB; Semon JH; Pavelic ZP
Antibiot Chemother (1971); 1978; 23():295-304. PubMed ID: 306219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
